| 511 |
GARDASIL 9 |
HUMAN PAPILOMAVIRUS TYPE 6 30 MCG,TYPE 11 40 MCG, TYPE 16 60 MCG, TYPE 18 40 MCG, TYPE 31 20 MCG, TYPE 33 20 MCG, TYPE 45 20 MCG, TYPE52 20 MCG & TYPE 58 L1 PROTEIN 20 MCG |
SUSPENSION FOR INJECTION |
SYRINGE |
PRECANCEROUS LESIONS(GROWTHS) AND CANCER IN THE CERVIX, VULVA OR VAGINA AND ANUS, GENITAL WARTS |
No |
DKSH LAOS COMPANY LIMITED |
MERCK SHARP & DOHME CORP, |
USA |
CERTIFICATE RELEASED |
06 I 4717/19 |
2023-03-31 |
2026-03-30 |
View |
| 512 |
GAVISCON DUAL ACTION LIQUID |
SODIUM ALGINATE 500 MG, SODIUM BICARBONATE 213 MG, CALCIUM CARBONATE 325 MG |
SUSPENSION |
SACHET, BOTTLE |
TREATMENT OF SYMPTOMS RESULTING FROM THE REFLUX OF ACID, BILE AND PEPSIN INTO THE OESOPHAGUS SUCH AS ACID REGURGITATION, HEARTBURN AND INDIGESTION, FOR EXAMPLE FLLOWING MEALS OR DURING PREGNANCY, AND FOR SYMOMS OF EXCESS STOMACH ACID, CAN ALSO BE USED TO TREAT THE SYMPTOMS OF GASTRO-ESOPHAGEAL REFLUX DURING CONCOMITANT TREATMENT WITH OR FOLLOWING WITHDRAWAL OF ACID SUPPRESSION THERAPY |
No |
DKSH LAOS COMPANY LIMITED |
RECKITT BENCKISER HEALTHCARE(UK)LIMITED |
UNITED KINGDOM |
CERTIFICATE RELEASED |
01 I 5372/23 |
2023-01-23 |
2026-01-22 |
View |
| 513 |
GAVISCON SUSPENSION |
SODIUM ALGINATE 500 MG, SODIUM BICARBONATE 267 MG, CALCIUM CARBONATE 160 MG |
SUSPENSION |
SACHET |
TREATMENT OF SYMPTOMS OF GASTRO-OESOPHAGEAL REFLUX SUCH AS ACID REGURGITATION, HEARTBURN AND INDIGESTION RELATED TO REFLUX, FOR EXAMPLE, FOLLOWING MEALS, OR DURING PREGNANCY, OR IN PATIENTS WITH SYMPTOMS RELATED TO REFLUX OESOPHAGITIS |
No |
DKSH LAOS COMPANY LIMITED |
RECKITT BENCKISER HEALTHCARE(UK)LIMITED |
UNITED KINGDOM |
CERTIFICATE RELEASED |
01 I 5373/23 |
2023-01-23 |
2026-01-22 |
View |
| 514 |
GLAKAY 15MG |
MENATETRENONE 15MG |
CAPSULE |
BLISTERPACK |
IMPROVEMENT OF BONE MASS DECREASE AND RELIEF OF BACK PAIN IN PATIENTS WITH OSTEOPOROSIS |
No |
DKSH LAOS COMPANY LIMITED |
SHIBAKAWA PLANT OF FUJI CAPSULE CO.,LTD |
THAILAND |
CERTIFICATE RELEASED |
01 I 2871/07 |
2023-03-31 |
2026-03-30 |
View |
| 515 |
GLIFORWAN FORTE 2.5 |
METFORMIN HYDROCHLORIDE USP 500 MG, GLIBENCLAMIDE BP 2.5 MG |
FILM COATED TABLET |
ALU-PVC BLISTER |
TREATMENT OF TYPE 2 DIABETES IN ADULTS, AS REPLACEMENT FOR PREVIOUS COMBINATION THERAPY WITH METFORMIN AND GLIBENCLAMIDE IN PATIENTS WHOSE GLYCAEMIA IS STABLE AND WELL-CONTROLLED. |
No |
DKSH LAOS COMPANY LIMITED |
MASCOT HEALTH SERIES PVT.LTD |
INDIA |
CERTIFICATE RELEASED |
02 I 5693/24 |
2024-02-26 |
2027-02-25 |
View |
| 516 |
GLIFORWAN FORTE 5 |
METFORMIN HYDROCHLORIDE USP 500 MG, GLIBENCLAMIDE BP 5 MG |
FILM COATED TABLET |
ALU-PVC BLISTER |
TREATMENT OF TYPE 2 DIABETES IN ADULTS, AS REPLACEMENT FOR PREVIOUS COMBINATION THERAPY WITH METFORMIN AND GLIBENCLAMIDE IN PATIENTS WHOSE GLYCAEMIA IS STABLE AND WELL-CONTROLLED. |
No |
DKSH LAOS COMPANY LIMITED |
MASCOT HEALTH SERIES PVT.LTD |
INDIA |
CERTIFICATE RELEASED |
02 I 5694/24 |
2024-02-26 |
2027-02-25 |
View |
| 517 |
GLUCOPHAGE 500 MG |
METFORMIN HYDROCHLORIDE 500 MG EQ.TO METFORMIN BASE 390 MG |
FILM COATED TABLET |
PVC-ALUMINIUM |
TREATMENT OF TYPE 2 DIABETES IN ADULT, PARTICULARLY IN OVERWEIGHT PATIENTS, WHEN DIETARY MANAGEMENT AND EXCERCISE ALONE DOES NOT RESULT IN ADEQUATE GLYCAEMIC CONTROL |
Yes |
DKSH LAOS COMPANY LIMITED |
MERCK SANTE S.A.S |
FRANCE |
CERTIFICATE RELEASED |
02 I 5045/21 |
2024-06-22 |
2027-06-21 |
View |
| 518 |
GLUCOPHAGE 850 MG |
METFORMIN HYDROCHLORIDE 850 MG EQ.TO METFORMIN BASE 662.90 MG |
FILM COATED TABLET |
PVC-ALUMINIUM |
TREATMENT OF TYPE 2 DIABETES IN ADULT, PARTICULARLY IN OVERWEIGHT PATIENTS, WHEN DIETARY MANAGEMENT AND EXCERCISE ALONE DOES NOT RESULT IN ADEQUATE GLYCAEMIC CONTROL |
Yes |
DKSH LAOS COMPANY LIMITED |
MERCK SANTE S.A.S |
FRANCE |
CERTIFICATE RELEASED |
02 I 5046/21 |
2024-06-22 |
2027-06-21 |
View |
| 519 |
GLUCOVANCE 500 MG/2.5 MG |
METFORMIN HYDROCHLORIDE 500 MG, GLIBENCLAMIDE 2.5 MG |
FILM COATED TABLET |
PVC-PVDC BLISTER |
TREATMENT OF TYPE 2 DIABETES IN ADULT, AS REPLACEMENT FOR PREVIOUS COMBINATION THERAPY WITH METFORMIN AND GLIBENCAMIDE IN PATIENTS WHOSE GLYCAEMIA IS STABLE AND WELL-CONTROLLED. |
No |
DKSH LAOS COMPANY LIMITED |
MERCK SANTE S.A.S |
FRANCE |
CERTIFICATE RELEASED |
02 I 5047/21 |
2024-06-22 |
2027-06-21 |
View |
| 520 |
GLUCOVANCE 500 MG/5MG |
METFORMIN HYDROCHLORIDE 500 MG, GLIBENCLAMIDE 5 MG |
FILM COATED TABLET |
PVC-PVDC BLISTER |
TREATMENT OF TYPE 2 DIABETES IN ADULT, AS REPLACEMENT FOR PREVIOUS COMBINATION THERAPY WITH METFORMIN AND GLIBENCAMIDE IN PATIENTS WHOSE GLYCAEMIA IS STABLE AND WELL-CONTROLLED. |
No |
DKSH LAOS COMPANY LIMITED |
MERCK SANTE S.A.S |
FRANCE |
CERTIFICATE RELEASED |
02 I 5048/21 |
2024-06-22 |
2027-06-21 |
View |
